| Not Yet Recruiting | RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy NCT07218692 | City of Hope Medical Center | Phase 2 |
| Not Yet Recruiting | Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer NCT07383441 | SWOG Cancer Research Network | Phase 3 |
| Not Yet Recruiting | VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell C NCT07510334 | Mayo Clinic | Phase 2 |
| Recruiting | Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatm NCT07128680 | City of Hope Medical Center | Phase 1 |
| Enrolling By Invitation | Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcino NCT07488572 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | Radiopharmaceutical Treatment of Advanced Kidney Cancer NCT06783348 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Withdrawn | PSMA Therapy and Immunotherapy in Kidney Cancer NCT06361810 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Recruiting | Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC) NCT07179770 | NYU Langone Health | Phase 1 |
| Recruiting | Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Rena NCT07011719 | Arcus Biosciences, Inc. | Phase 3 |
| Recruiting | Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Ki NCT06866262 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Imaging of Solid Tumors Using 18F-TRX NCT06942104 | Rahul Aggarwal | Phase 1 |
| Recruiting | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer NCT06399419 | Osel, Inc. | Phase 1 |
| Recruiting | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642 | Mayo Clinic | — |
| Suspended | Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients with Metastatic Clear Cell Re NCT06059014 | Centre Leon Berard | Phase 1 / Phase 2 |
| Unknown | 68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma NCT05879471 | Peking Union Medical College Hospital | Phase 2 |
| Recruiting | Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study NCT05361720 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Terminated | Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer NCT04904302 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cel NCT05012371 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | [18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma NCT06428708 | Western University | EARLY_Phase 1 |
| Active Not Recruiting | CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cance NCT05122546 | City of Hope Medical Center | Phase 1 |
| Recruiting | Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Ki NCT04510597 | SWOG Cancer Research Network | Phase 3 |
| Terminated | Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery NCT04370509 | University of California, San Francisco | Phase 2 |
| Active Not Recruiting | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers NCT04388852 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) NCT03679767 | Incyte Corporation | Phase 2 |
| Terminated | Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer NCT03260504 | University of Washington | Phase 1 |
| Terminated | Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastat NCT03334409 | Academic and Community Cancer Research United | Phase 2 |
| Terminated | Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma NCT02781506 | University of Texas Southwestern Medical Center | Phase 2 |
| Completed | Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell R NCT02848768 | Rennes University Hospital | — |
| Completed | High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer NCT01896271 | University of Texas Southwestern Medical Center | Phase 2 |
| Completed | Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 NCT01510119 | Abramson Cancer Center at Penn Medicine | Phase 1 / Phase 2 |
| Terminated | A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma NCT01391130 | Eli Lilly and Company | Phase 2 |
| Completed | Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer NCT02002312 | Radboud University Medical Center | Phase 2 |